Medivie Therapeutic (Israel) Probability of Future Stock Price Finishing Under 112.24
| MDVI Stock | ILA 37.00 0.10 0.27% |
Medivie |
Medivie Therapeutic Target Price Odds to finish below 112.24
The tendency of Medivie Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under 112.24 after 90 days |
| 37.00 | 90 days | 112.24 | close to 99 |
Based on a normal probability distribution, the odds of Medivie Therapeutic to stay under 112.24 after 90 days from now is close to 99 (This Medivie Therapeutic probability density function shows the probability of Medivie Stock to fall within a particular range of prices over 90 days) . Probability of Medivie Therapeutic price to stay between its current price of 37.00 and 112.24 at the end of the 90-day period is about 85.28 .
Assuming the 90 days trading horizon Medivie Therapeutic has a beta of -0.65. This indicates as returns on the benchmark increase, returns on holding Medivie Therapeutic are expected to decrease at a much lower rate. During a bear market, however, Medivie Therapeutic is likely to outperform the market. Additionally Medivie Therapeutic has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Medivie Therapeutic Price Density |
| Price |
Predictive Modules for Medivie Therapeutic
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Medivie Therapeutic. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Medivie Therapeutic Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Medivie Therapeutic is not an exception. The market had few large corrections towards the Medivie Therapeutic's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Medivie Therapeutic, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Medivie Therapeutic within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.68 | |
β | Beta against Dow Jones | -0.65 | |
σ | Overall volatility | 10.68 | |
Ir | Information ratio | -0.14 |
Medivie Therapeutic Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Medivie Therapeutic for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Medivie Therapeutic can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Medivie Therapeutic generated a negative expected return over the last 90 days | |
| Medivie Therapeutic has high historical volatility and very poor performance | |
| Medivie Therapeutic has accumulated 3.19 M in total debt with debt to equity ratio (D/E) of 0.85, which is about average as compared to similar companies. Medivie Therapeutic has a current ratio of 0.64, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Medivie Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Medivie Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medivie Therapeutic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medivie to invest in growth at high rates of return. When we think about Medivie Therapeutic's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 491 K. Net Loss for the year was (6.59 M) with loss before overhead, payroll, taxes, and interest of (603 K). | |
| Medivie Therapeutic has accumulated about 4.15 M in cash with (3.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44. | |
| Roughly 72.0% of Medivie Therapeutic outstanding shares are owned by corporate insiders |
Medivie Therapeutic Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Medivie Stock often depends not only on the future outlook of the current and potential Medivie Therapeutic's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Medivie Therapeutic's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.9 M |
Medivie Therapeutic Technical Analysis
Medivie Therapeutic's future price can be derived by breaking down and analyzing its technical indicators over time. Medivie Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Medivie Therapeutic. In general, you should focus on analyzing Medivie Stock price patterns and their correlations with different microeconomic environments and drivers.
Medivie Therapeutic Predictive Forecast Models
Medivie Therapeutic's time-series forecasting models is one of many Medivie Therapeutic's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Medivie Therapeutic's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Medivie Therapeutic
Checking the ongoing alerts about Medivie Therapeutic for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Medivie Therapeutic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Medivie Therapeutic generated a negative expected return over the last 90 days | |
| Medivie Therapeutic has high historical volatility and very poor performance | |
| Medivie Therapeutic has accumulated 3.19 M in total debt with debt to equity ratio (D/E) of 0.85, which is about average as compared to similar companies. Medivie Therapeutic has a current ratio of 0.64, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Medivie Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Medivie Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medivie Therapeutic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medivie to invest in growth at high rates of return. When we think about Medivie Therapeutic's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 491 K. Net Loss for the year was (6.59 M) with loss before overhead, payroll, taxes, and interest of (603 K). | |
| Medivie Therapeutic has accumulated about 4.15 M in cash with (3.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44. | |
| Roughly 72.0% of Medivie Therapeutic outstanding shares are owned by corporate insiders |
Other Information on Investing in Medivie Stock
Medivie Therapeutic financial ratios help investors to determine whether Medivie Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medivie with respect to the benefits of owning Medivie Therapeutic security.